



## INVITATION TO PRESENTATION OF ACARIX´S THIRD QUARTER REPORT 2022

**Acarix will publish its third quarter results on Wednesday 16 November 2022 at 08.00 am (CEST). A live webcast will be held at 16.30 (CEST) the same day, where CEO Helen Ljungdahl Round and CFO Christian Lindholm will present the report. The presentation ends with a Q&A together with Redeye's analysts, where you can ask the company questions via the form on the live page.**

The webcast will be available at <https://www.redeye.se/events/853972/live-q-acarix-2>

The presentation will be available at <https://www.acarix.com/for-investors/investor-presentations> after publication of the report.

### **For more information contact:**

Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [helen.round@acarix.com](mailto:helen.round@acarix.com)

Christian Lindholm, CFO, phone +46 705 118333, email [christian.lindholm@acarix.com](mailto:christian.lindholm@acarix.com)

### **About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)) is Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com).

### **Attachments**

[Invitation to presentation of Acarix´ s third quarter report 2022](#)